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a b s t r a c t
This study presents a MLC-based, 3D grid-therapy technique with characteristics of both 3D-conformalradiotherapy and grid-therapy. It generates a brachytherapy-like dose distribution, with D50% of 20, 9.8,
5.4 and 2.9-Gy, for the spheres, target, 1 cm-outershell and 2 cm-outershell, respectively. It may provide a
strategy to deliver ablative doses to large tumors safely.
Ó 2015 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 117 (2015) 483–486
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Grid therapy (GT), or spatially fractionated radiotherapy (SFRT),
which uses a grid collimator to block discrete parts of radiation in
the treatment field, was first implemented clinically in the orthovoltage era to treat deep seated tumors [1,2]. This concept was
based on the finding that skin and subcutaneous tissue can tolerate
much higher doses with such treatment, because the areas blocked
by the grid can serve as regrowth centers for normal tissues [1,2].
Similarly, deep-seated organs may also tolerate higher peak doses
with such treatment due to a volume effect [3]. Megavoltage-based
GT, which usually gives a large dose (10–20 Gy) in a single fraction
before a conventional radiotherapy regimen, has been implemented to debulk large tumors [4–6]. The treatment is well tolerated, with good responses and outcomes [5]. Based on the same
principle, microbeam radiotherapy (MRT) systems with low energy
(10–100 kV) from synchrotron wigglers have been developed [7,8].
Studies showed that mouse brains could tolerate up to 650 Gy peak
dose in single fraction using this highly spatially modulated MRT
[6–9]. While the application for the MRT was limited due to its
low energy, a minibeam system with higher energies and wider
apertures [10], and various other approaches [11–15] were
recently proposed, suggesting continuous interests of GT in
radiotherapy.
However, the application of GT has not been popular in the
mainstream radiation oncology, mainly due to the concern of
⇑ Corresponding author at: Department of Radiology/Radiation Oncology, Georgia
Regents University, Augusta GA 30912, United States.
E-mail address: jjin@gru.edu (J.-Y. Jin).

underdosing portions of the tumor. Although bystander effect
and damage of tumor vascular structure were speculated to contribute to the promising clinical outcomes of the GT technique,
its underlying mechanisms have not been fully elucidated [5,16].
Recently, studies have shown that the immune response may play
an important role in tumor control during radiotherapy [17,18].
Tumor control has been reported to depend on the competing
result between anti-tumor immune response and tumor cell
repopulation [19]. Animal studies and single case clinical reports
have demonstrated that a combination of immunotherapy with
radiotherapy exhibits not only a synergetic effect in tumor control
within the radiation treatment field(s), but also an abscopal effect
to control the tumor outside the radiotherapy treatment field(s)
[17–21]. In addition, these synergetic and abscopal effects are
more prominent when using hypofractionated stereotactic body
radiotherapy (SBRT) [17,18,21,22]. Therefore, clinical trials combining SBRT with immunotherapy for various cancers are under
investigation [22].
SBRT is not typically used for large tumors due to potential normal tissue complications. Given the ability to offer superior sparing
of normal tissues due to the volume effect, GT appears to be an
attractive option to replace SBRT and test the hypothesis that the
combination of radiotherapy with immunotherapy will synergistically improve tumor control for larger tumors. However, conventional 2D GT techniques, including the multileaf-collimator (MLC)
based technique [15], use only one field. They do not have the characteristics of 3D conformal dose distribution as shown in multiplefield 3D conformal radiotherapy (3DCRT) or intensity modulated

http://dx.doi.org/10.1016/j.radonc.2015.07.047
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leaf-width of 2.5 mm was used. A simultaneous boost IMRT plan
with 9 non-coplanar beams of a single isocenter, 8-Gy to the
GTV, 20-Gy to the boost volume, was generated by maximizing
dose to the spheres, constraining the 8-Gy dose to the other
regions of the GTV, and minimizing dose to the 2 shells.
Normalized cumulative dose–volume histograms (DVHs) of the
GTV, boost volume, and two shells were calculated. The dose grid
calculation resolution was 1 mm.
The treatment plan was mapped to a phantom. GafchromicTM
EBT3 film (International Specialty Products, Wayne, NJ) was placed
in the coronal plane to measure the delivered dose distribution.
The radiation was delivered using a Novalis TXTM linear accelerator
(Varian Medical System) at 6X, in SRS mode, with a dose rate of
1000 MU/min. Dose calibration for the EBT3 film was also performed the same day. The EBT3 films were read 24 h after dose
delivery through an Epson 10000XL Flatbed scanner (Epson
America, Inc, Long beach, CA). An in-house developed protocol
was used for film dosimetric analysis. The measured dose distribution was compared with the dose distribution from the treatment
plan.

radiotherapy (IMRT). 3D SFRT has been proposed by delivering
focused radiation to several vertices inside the target using
Cyberknife or Gammaknife [13]. However, such 3D SFRT approach
may not achieve optimal dose distribution for GT, because the
large number of small-field beams that focus on the vertices are
in various directions, thus inevitably overlap with each other at
various positions other than the vertices, especially when the number of vertices increases. This study aims to develop an accelerator/
MLC-based 3D SFRT technique that can limit the overlaps mainly at
the vertices using so-called channeling-direction beams. The term
‘‘SFRT” rather than GT is used for this technique because no
physical grid is used.
Material and methods
The technique is similar to other 3D SFRT approaches in terms
that vertices (small spheres) were first created within the gross
tumor volume (GTV) [13]. However, it differs from others in following aspects: (1) a much larger number of spheres were created
and were orderly positioned to form a lattice; (2) only beams in the
channeling direction, in which the spheres are all perfectly aligned
in its beam’s eye views (BEV), were chosen so that radiation grids
of different beams would cross-fire at the spheres; (3) the spheres
were used as boost volume and a simultaneous boost IMRT technique was employed to generate a radiation grid pattern for each
field. Consequently, the spheres would receive high dose due to
the cross-firing of radiation grids, while the remaining area of
the GTV would receive a dose lower than the spheres, but higher
than the most of the normal structures outside the target, because
of the contribution of scattering radiation (valley dose of the radiation grids) from all the fields. A limited number of channeling
directions exist for the lattice. For coplanar setting, the useful
channeling directions are gantry-angle = 0°, 45°, 90°, 315°, and
their parallel opposing directions, as illustrated in Fig. 1a. For
non-coplanar setting, there are 5 additional directions available,
including the combination of table-angle = 90°, and gantryangle = 45°, 90° or 135°.
The technique was tested in a glioblastoma patient with a large
GTV (112.9 cubic centimeter). A lattice composed of 103 spheres
(diameter = 5-mm, sphere-to-sphere distance = 15-mm) was first
generated using an in-house computer program, and imported into
the Eclipse treatment planning system (Varian Medical System Inc,
Palo Alto, CA) as a structure of the patient. The lattice and GTV
were combined to form the boost target volume using a Boolean
operation. Fig. 1b–d shows 3D view of the boost spheres, and alignment of the spheres in BEVs of 2 different channeling directions,
respectively. Two outer-shells (shell-1 cm and shell-2 cm), with
10-mm in thickness, and their outer surface 10 and 20 mm away
from the GTV surface were created to evaluate the dose outside
the GTV. The Varian HD120TM MLC (Varian Medical Systems) with

a

Results
The technique generated a dose distribution that shows the
important characteristics of both 3DCRT and SFRT. As shown in
Fig. 2a–e, the doses within the target are spatially modulated, similar to interstitial brachytherapy, with high doses in the spheres,
and relatively low doses (40–80% of the peak dose) outside the
spheres. The spillage doses outside the GTV were also spatially
modulated, with some discrete hot spots (40–60% of the peak dose,
from overlaps) in regions close to the target (such as Shell-1 cm
and Shell-2 cm). More importantly, the spillage doses were much
lower than the doses in the target (mostly in the range of 10–
30% of the peak dose), and gradually decreases with the distance
from the target. This characteristic was similar to 3DCRT or
IMRT. Fig. 2f shows the DVH of the spheres, GTV, and two shell
structures. The dose to 95%, 50% and 5% of the volume (D95%,
D50%, D5%) for the spheres were 18.5, 20.0, and 21.4 Gy, respectively. The corresponding doses were 7.9, 9.8, 16.1 Gy for the
GTV, 2.8, 5.4, and 10.3 Gy for Shell-1 cm, and 1.4, 2.9, and 5.8 Gy
for Shell-2 cm, respectively. Total MU was 15291. This
accelerator/MLC-based 3D SFRT plan was successfully delivered
to a phantom. Total beam-on time was approximately 15 min
using the 6X-SRS mode with 1000 MU/min.
Film dosimetry showed good agreement between the treatment
planned and delivered doses. Fig. 2g–i shows the comparison of the
dose distribution between the plan and measurement by film
dosimetry in a coronal plane. A Gamma index with criteria 3%/
1 mm showed a passing rate of >95% for a rectangular region
including the target and significant extensions outside the target

b

c

d

Fig. 1. Illustration of the lattice of spheres and the selection of the channeling directions: (a) illustration of the channeling directions that have perfect alignment of spheres in
beam’s eye view (BEV) for an axial plane. The arrows point to the channeling directions (a total of 8 directions, with 4 useful directions, and 4 corresponding parallel opposing
directions). (b) 3D view of the lattice of spheres within the target. (c) Alignment of the spheres in the BEV for a lateral beam (table = 0°, gantry = 90°). (d) Alignment of the
spheres in the BEV for a left anterior oblique beam (table = 0°, gantry = 45°).
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Fig. 2. Planning and film dosimetry results: (a) isodose distribution in an axial plane; (b) in a coronal plane; (c) in a sagittal plane; (d) in a 3D view. (e) Dose profiles along 3
lines (left, right and anterior) marked in (a). (f) Dose–volume histograms (DVHs) of structures. (g) Planned 2D dose distribution in a coronal plane. (h) Measured 2D dose
distribution in the same plane. (i) Comparison of planned and measured dose profiles for 4 different regions (spheres, superior, left and inferior) represented by 4 lines in (g).

(as shown in Fig. S1 in Supplementary material). The largest difference was the dose at the center of each sphere within the target.
The difference had a range of 1–6%, with an average of 2.8%.
Comparisons of dose profiles through a line crossing the vertices
within the target, and 3 lines outside the target showed excellent
agreement between the planned and delivered doses. These dose
profiles also showed grid-like dose distributions both inside and
outside the target. The peak to valley dose ratio (PVDR) ranged
from 2–2.5.

Discussion
We have developed a MLC-based 3D SFRT technique, which
shows the characteristics of both 3DCRT and SFRT, and may apply
to large tumors with single- or multi-fraction treatment (ablative
or non-ablative). For a dose of 20 Gy/fraction to 50% of sphere volume, 95% of GTV receives 7.9 Gy/fraction. The 1-cm outer-shell,
which is usually the clinical target volume and/or planning target
volume in conventional radiotherapy, and is composed of both normal tissue and microscopic diseases, receives 5.4 Gy/fraction for
50% of its volume. The 2 cm outer-shell, which is mainly normal
tissue, receives 2.9 Gy/fraction for 50% of its volume. The dose

further decreases for normal structures further away from the target. The ablative dose (20 Gy/fraction) in the spheres may destroy
anything within the spheres and augments an anti-cancer immune
response. The relatively large dose (8 Gy/fraction) within the GTV
may kill a large fraction of tumor cells and substantially reduce the
tumor burden. On the other hand, the reduced (comparing to 2D
GT) and spatially-fractionated dose (comparing to 3DCRT or
IMRT) to the normal structures may minimize damage to the
organs at risk and the immune system. The technique is also not
limited to hypofractionated radiotherapy. For example, the dose
to the spheres can be reduced to 5 Gy/fraction. Consequently, the
dose to GTV is reduced to 2 Gy/fraction, and the doses to the 2
shells are also reduced correspondingly. The technology can be
readily implemented for centers with IMRT capability. The treatment time is reasonable, and may be further reduced using a
flattening-filter-free machine which offers higher dose rate (1400
and 2400 MU/min for Varian TrueBeamTM 6X-FFF and 10X-FFF).
The PVDR is approximately 2–2.5 in this study. It can be varied
by changing the sphere size and lattice distance. For non-cranial
lesions, only coplanar beams may be used so that the maximum
beam number is 4. The PVDR in such cases may be higher than that
in the cranial case if the same lattice parameters are used. In addition, setup uncertainty, patient motion, especially the respiratory
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motion may also change the PVDR. The agreement in film dosimetry suggests that the effect of setup uncertainty to PVDR is minimal
for the phantom setting in a clinical linear accelerator system, in
which the uncertainty is mainly due to isocenter variation with different table and gantry angles. It is not clear what PVDR value and
fractionation regimen are the optimal. The choice of the optimal
parameters may depend on the underlying mechanisms of how
the immune system, radiation, and tumor interact with each other.
These interactions may include radiation killing of tumor cells and
immune cells, and the generation and stimulation of the immune
response against the tumor by radiation induced tumor cell death.
In some cases, using SFRT instead of conventional RT may change
the pattern of these interactions, and may shift the balance toward
more tumor cell killing by immune system.
A major difference of this 3D SFRT technique from the previous
single beam based 2D GT approaches [5–12,14,15] is that it uses
multiple beams from different gantry angles so that it exhibits a
characteristic of 3DCRT. That is, the radiation dose conforms with
the target, and gradually decreases in the surrounding normal tissues with the distance from the target. Our technique also differs
from the previous 3D lattice radiotherapy [13] because we only
use beams at special tunneling directions. Consequently, the characteristic of GT represented by the PVDR would not degrade with
increasing the number of lattice spheres. However, the limitation
of this work is that it is just a dosimetrical study. Therefore, its
potential clinical application is based on the following hypotheses:
(1) there is a bystander or abscopal effect in radiation tumor killing; (2) an ablative radiation dose may kill the tumor vascular
structures and enhance tumor killing; (3) there is a volume effect
in radiation damage of normal tissue. Further animal and clinical
studies are needed to verify the hypotheses.
In summary, we have demonstrated a MLC-based inversely
optimized 3D-SFRT technique, achieving a brachytherapy-like dose
distribution. Ablative high-dose radiation can be delivered to the
lattice of spheres for large tumors, with much lower and gridlike safe doses to the surrounding normal tissue. Clinical studies
are needed to validate the safety and efficacy of this technology.
Conflict of interest
None.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2015.07.
047.
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